Click on the image to access our comprehensive Ranibizumab (Lucentis®) information page. Ranibizumab (Lucentis®) is a medication used to treat wet age-related macular degeneration and diabetic macular edema, among other retinal diseases, in adults. This page contains detailed prescribing information, so you can make an informed decision on the use of Ranibizumab (Lucentis®).

 

 

Ranimizumab (Lucentis) Product Safety Information - Diabetic Macular Edema (DME)

Download the PDF here >>

 

Ranimizumab (Lucentis) Product Safety Information - Neovascular (Wet) Age-Related Macular Degeneration (wAMD)

Download the PDF here >>

 

Ranimizumab (Lucentis) Product Safety Information - Retinal Vein Occlusion (RVO)

Download the PDF here>>

 

Ranimizumab (Lucentis) Product Safety Information - Proliferative Diabetic Retinopathy (PDR)

Download the PDF here>>

 

Ranimizumab (Lucentis) Product Safety Information - Choroidal Neovascularization (CNV)

Download the PDF here>>

 

Do you find this content useful?: 
No votes yet
PH2209066405
×

Medical Information Request

×

Ask Speakers